Acute Interstitial Nephritis with the Nephrotic Syndrome Following Recombinant Leukocyte A Interferon Therapy for Mycosis Fungoides

Authors:
  • SASteven D. Averbuch
    Steven D. Averbuch
  • HAHoward A. Austin
    Howard A. Austin
  • SSStephen A. Sherwin
    Stephen A. Sherwin
  • TATatiana Antonovych
    Tatiana Antonovych
  • PBPaul A. Bunn
    Paul A. Bunn
  • DLDan L. Longo
    Dan L. Longo
Publisher website
Google Scholar
Abstract
RECOMBINANT leukocyte A interferon is a highly purified single molecular species of alpha interferon that is produced by recombinant-DNA methods and has been shown to have biologic activity.1 The compound is currently being tested in patients with cancer in order to assess its toxicity and therapeutic efficacy.2 3 4 Previously reported side effects include fever, chills, fatigue, anorexia, myalgias, nausea and vomiting, headache, and dose-dependent, reversible leukopenia and hepatic transaminase elevations.2 3 4 We report here on a patient who had reversible acute renal insufficiency and the nephrotic syndrome after being treated with recombinant leukocyte A interferon for mycosis fungoides. The clinical syndrome and . . .

This publication has 17 references indexed in Scilit: